Nikolaus R McFarland

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system
    Nikolaus R McFarland
    MassGeneral Institute for Neurodegenerative Disease MIND, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129 4404, USA
    J Neurochem 109:838-45. 2009
  2. pmc Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease
    Nikolaus R McFarland
    MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129 4404, USA
    J Neuropathol Exp Neurol 68:515-24. 2009
  3. ncbi request reprint Direct detection of alpha synuclein oligomers in vivo
    Hemi Dimant
    MassGeneral Institute for Neurodegenerative Disease, Department Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
    Acta Neuropathol Commun 1:6. 2013
  4. pmc Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders
    Nikolaus R McFarland
    Center for Translational Research in Neurodegenerative Disease, Department of Neurology, University of Florida College of Medicine, Gainesville, Fla, USA
    Neurodegener Dis 12:189-98. 2013

Collaborators

Detail Information

Publications4

  1. pmc Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system
    Nikolaus R McFarland
    MassGeneral Institute for Neurodegenerative Disease MIND, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129 4404, USA
    J Neurochem 109:838-45. 2009
    ..New rAAV serotypes thus promise improved gene delivery to nigrostriatal system with the potential for better models and therapeutics for Parkinson disease and other neurodegenerative disorders...
  2. pmc Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease
    Nikolaus R McFarland
    MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129 4404, USA
    J Neuropathol Exp Neurol 68:515-24. 2009
    ..Further study is needed to clarify the effects of these S129 mutants and alpha-synuclein phosphorylation in mammalian systems...
  3. ncbi request reprint Direct detection of alpha synuclein oligomers in vivo
    Hemi Dimant
    MassGeneral Institute for Neurodegenerative Disease, Department Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
    Acta Neuropathol Commun 1:6. 2013
    ....
  4. pmc Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders
    Nikolaus R McFarland
    Center for Translational Research in Neurodegenerative Disease, Department of Neurology, University of Florida College of Medicine, Gainesville, Fla, USA
    Neurodegener Dis 12:189-98. 2013
    ..In Parkinson's disease (PD) higher, but still normal, levels of blood and cerebrospinal fluid urate have been associated with a lower rate of disease progression...